Values as of: 2024-11-03
COMMON STOCK | Health Information Services |
Last Closing
USD 9.2Change
0.00 (0.00)%Market Cap
USD 6.89BVolume
N/AAnalyst Target
N/AVerdict
Verdict
M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates through five reporting segments: Medical Platform, Evidence Solutions, Career Solutions, Site Solutions, and Overseas. It operates m3.com, a members-only web site for providing information to the healthcare professionals; MR-kun, where member doctors can independently and continuously receive information on the m3com platform; QOL-kun that provides life support information other than medical information to members; AskDoctors, where registered doctors answer questions about health and illness from the general public; MDLinx for medical professionals in the United States; and Doctors.net.uk, a website that provides developing services for pharmaceutical companies, as well as provides drug information database in France, Germany, and Spain. The company also provides career services for doctors and pharmacists, recruitment, and posting job advertisements through m3.com CAREER. In addition, it engages in the sales activities and marketing operations for pharmaceuticals and medical devices; development, sale, and support business of electronic medical records and medical equipment for medical institutions; survey service for medical professionals; sale and marketing support businesses for pharmaceutical companies, etc. through the Internet; provision of management support and consulting services to medical institutions, and home-visit nursing services; and provision of human resources services for healthcare professionals, as well as operates clinical trial facilities. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
Company Website : https://corporate.m3.com
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| L0T:F | GE HEALTHCARE TECH.INC. |
N/A |
USD 37.77B |
| 2HE:F | Healthequity Inc |
N/A |
USD 6.90B |
| 6HL0:F | R1 RCM Inc |
N/A |
USD 5.57B |
| 9EH:F | Evolent Health Inc |
N/A |
USD 2.44B |
| OC9:F | Omnicell Inc |
N/A |
USD 2.04B |
| 1KJ:F | 10X GENOMICS DL -00001 |
N/A |
USD 1.73B |
| 6JM:F | JMDC INC. |
N/A |
USD 1.69B |
| 1XZ:F | Ping An Healthcare and Technol.. |
N/A |
USD 1.55B |
| 4LL:F | Teladoc Inc |
N/A |
USD 1.50B |
| 19P:F | Phreesia Inc |
N/A |
USD 0.98B |
N/A
| Market Performance vs. Industry/Classification (Health Information Services) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -36.99% | 29% | F | 18% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -36.99% | 29% | F | 18% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -38.26% | 36% | F | 17% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -38.26% | 36% | F | 17% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -21.72% | 21% | F | 9% | A- | ||
| Dividend Return | 7.64% | 76% | C+ | 56% | F | ||
| Total Return | 29.37% | 92% | A | 86% | B+ | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 32.33% | 36% | F | 39% | F | ||
| Risk Adjusted Return | 23.65% | 74% | C | 50% | F | ||
| Market Capitalization | 6.89B | 97% | N/A | 82% | B | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
